Squamous cell carcinoma

10 trials 2 recruiting MedDRA PT
10 Registered trials
2 Recruiting
9 Unique sponsors
4 Unique IMPs
8 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 5
Mechanism of action (INN-stem analysis)
Receptor fusion protein 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Platinum compound 1 substance
Monoclonal antibody (immune) 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 3 Phase I: 3 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

1 trial
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2022-500395-57-00 11 countries 2019 n=267
    Ended

Phase II/III

1 trial
  • Cancer Trials Ireland Academic
    CISPLATIN
    2024-515237-15-00 1 country 2025 n=78
    Halted

Phase II

3 trials
  • Alx Oncology Inc. Commercial
    EVORPACEPT; PEMBROLIZUMAB
    2023-508340-22-00 3 countries 2021 n=50
    Ended
  • Alx Oncology Inc. Commercial
    EVORPACEPT; PEMBROLIZUMAB
    2023-508342-17-00 3 countries 2021 n=55
    Ended
  • Regeneron Pharmaceuticals Inc. Academic
    CEMIPLIMAB
    2022-500811-37-00 1 country 2021 n=6
    Ended

Phase I

3 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-509335-60-00 4 countries 2023 n=177
    Recruiting
  • Ikena Oncology Inc. Commercial
    IMP not specified
    2022-502622-40-00 4 countries n=31
    Ended
  • Nykode Therapeutics ASA Commercial
    IMP not specified
    2023-509996-18-00 2 countries 2022 n=40
    Ended

Phase I (Other)

1 trial
  • Exelixis Inc. Commercial
    IMP not specified
    2023-508267-69-00 5 countries 2023 n=222
    Ended

Phase I (First in Human)

1 trial
  • Scorpion Therapeutics Inc. Commercial
    IMP not specified
    2023-504807-94-00 7 countries 2023 n=178
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Alx Oncology Inc. Commercial 2 Phase II 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I 1
Ikena Oncology Inc. Commercial 1 Phase I 0
Nykode Therapeutics ASA Commercial 1 Phase I 0
Exelixis Inc. Commercial 1 Phase I (Other) 0
Merck Sharp & Dohme LLC Commercial 1 Phase III 0
Scorpion Therapeutics Inc. Commercial 1 Phase I (First in Human) 1
Cancer Trials Ireland Academic 1 Phase II/III 0
Regeneron Pharmaceuticals Inc. Academic 1 Phase II 0
New trials by year
2019
1
2021
3
2022
1
2023
3
2025
1
← All indication landscapes